Allogene Therapeutics Inc (NASDAQ:ALLO) shares, rose in value on Wednesday, July 09, with the stock price up by 0.83% to the previous day’s close as strong demand from buyers drove the stock to $1.21.
Actively observing the price movement in the last trading, the stock closed the session at $1.2, falling within a range of $1.19 and $1.265. The value of beta (5-year monthly) was 0.311. Referring to stock’s 52-week performance, its high was $3.78, and the low was $0.86. On the whole, ALLO has fluctuated by -14.79% over the past month.
With the market capitalization of Allogene Therapeutics Inc currently standing at about $264.67 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ALLO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ALLO currently trading nearly -3.97% and -4.55% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 46.71, while the 7-day volatility ratio is showing 6.94% which for the 30-day chart, stands at 7.21%. Furthermore, Allogene Therapeutics Inc (ALLO)’s beta value is 0.34.
A comparison of Allogene Therapeutics Inc (ALLO) with its peers suggests the former has fared considerably weaker in the market. ALLO showed an intraday change of 0.83% in last session, and over the past year, it shrunk by -43.19%%.
Data on historical trading for Allogene Therapeutics Inc (NASDAQ:ALLO) indicates that the trading volumes over the past 10 days have averaged 3.56 and over the past 3 months, they’ve averaged 3.06 million. According to company’s latest data on outstanding shares, there are 218.60 million shares outstanding.
Nearly 31.65% of Allogene Therapeutics Inc’s shares belong to company insiders and institutional investors own 66.02% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 26.04 million shares as on 2025-06-13, resulting in a short ratio of 7.91. According to the data, the short interest in Allogene Therapeutics Inc (ALLO) stood at 1442.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 27.36 million. The stock has fallen by -42.92% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ALLO stock heading into the next quarter.
